Research
Hormonal
Metabolic surgery reduces the risk of microvascular and macrovascular complications, as well as all-cause mortality, compared to non-surgical treatment in T2D patients.
Beyond weight loss, metabolic surgery significantly lowers the risk of diabetes-related organ damage (eyes, kidneys, nerves) and reduces the risk of early death compared to managing diabetes with medication and lifestyle changes alone.
StrongSupportsVERY_HIGH confidence
Metabolic surgery has also been shown to reduce microvascular and macrovascular events in T2D as compared to a nonsurgical group... Multiple cohort studies show all-cause mortality reduction with bariatric surgery.
Why this rating
Supported by large cohort studies and meta-analyses.
Source
Bariatric Surgery as a Long-Term Treatment for Type 2 Diabetes/Metabolic Syndrome
Zubaidah Nor Hanipah et al. · Annual Review of Medicine · 2020
DOI 10.1146/annurev-med-053117-123246
narrative_reviewCited 56×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →